<DOC>
	<DOC>NCT00403988</DOC>
	<brief_summary>Study Objective : To assess the efficacy and the safety of the combination of Oxaliplatin, and Vinorelbine with or without Trastuzumab as a salvage regimen in patients with Metastatic Breast Cancer</brief_summary>
	<brief_title>Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Metastatic, histologically or cytologically proven breast cancer. At least one bidimensionally measurable lesion. Previous treatment with chemotherapy as first line for metastatic disease is mandatory especially with anthracyclines +/ the Taxanes. Treatment as adjuvant is allowed. World Health OrganizationECOG performance status 02. Adequate renal function (Creatinine &lt;= 1.4 or Creatinine clearance &gt;= 30 ml/min) Adequate hepatic function (Liver Function Tests not more than 3 times the normal values) Adequate bone marrow reserve is required (Neutrophils (PMN) &gt;= 2000/mm2 and Platelets &gt;= 100,000/mm2) Patient who will receive Herceptin should have an overexpression of HER2neu. Symptomatic peripheral neuropathy (National Cancer Institute common toxicity criteria grade more than one). Pregnant or breastfeeding. History of prior malignancies (with the exception of excised cervical carcinomainsitu or nonmelanoma cell skin carcinoma). Receiving or had received, any treatment with experimental drugs. Had known brain or leptomeningeal involvement. Had a serious medical condition like congestive heart failure or an Ejection Fraction ≥ 40 %. The presence of bone as a sole site of metastasis. Radiation therapy to all areas of measurable disease less than four weeks before treatment. Creatinine two times above the normal range Hypercalcemia Evaluable but not a measurable disease as a sole site of metastasis: pleural effusion Ascites Pericardial effusion. Concomitant steroid intake for &gt; 4 weeks Bilirubin two times above the normal range The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>